Patents by Inventor Elena Burova

Elena Burova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250092139
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand 1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: February 15, 2024
    Publication date: March 20, 2025
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Publication number: 20240397919
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: August 13, 2024
    Publication date: December 5, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Publication number: 20240389563
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: August 15, 2024
    Publication date: November 28, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20240316361
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
    Type: Application
    Filed: April 24, 2024
    Publication date: September 26, 2024
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 12096754
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: September 24, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Patent number: 12089575
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: September 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20240298619
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: May 12, 2023
    Publication date: September 12, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
  • Patent number: 12024570
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 2, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson
  • Publication number: 20240166740
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 23, 2024
    Inventors: Erica ULLMAN, Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON
  • Publication number: 20230235089
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
    Type: Application
    Filed: November 23, 2022
    Publication date: July 27, 2023
    Inventors: Ella Ioffe, Elena Burova
  • Patent number: 11692032
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: July 4, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
  • Patent number: 11684050
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Programmed cell death 1 (Pdcd1) gene. The non-human animals, in some embodiments, comprise a genetic modification to an endogenous Pdcd1 gene so that the non-human animals express a PD-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: June 27, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Elena Burova, Alexander O. Mujica, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20210380702
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: August 11, 2021
    Publication date: December 9, 2021
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Publication number: 20210360908
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Patent number: 11117970
    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 14, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Andrew J. Murphy, Gavin Thurston, Ella Ioffe, Elena Burova
  • Patent number: 11102961
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 31, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Publication number: 20210105983
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Application
    Filed: December 3, 2020
    Publication date: April 15, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
  • Publication number: 20210040232
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: February 11, 2021
    Inventors: Aynur HERMANN, Ella IOFFE, Elena BUROVA, Gavin THURSTON, William OLSON
  • Patent number: 10881086
    Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: January 5, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Elena Burova, Yajun Tang, Ka-Man Venus Lai, Andrew J. Murphy
  • Patent number: 10844137
    Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston, William Olson